Palmitoyl Hexapeptide-12 vs Nonapeptide-1
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Biopeptide EL, Pal-VGVAPG
Palmitoyl hexapeptide-12 is the six-amino-acid sequence VGVAPG, a repeating piece of elastin, with a fatty acid tail attached so it can get into skin. It is sold under the trade name Biopeptide EL and pitched for firmness and elasticity, the bounce-back that fades with age. It is a cosmetic ingredient, not an FDA-approved drug, and nobody has published an independent clinical trial showing it visibly changes skin.
Also: Melanostatine 5, Melanostatine-5
Nonapeptide-1, sold as Melanostatine 5, is a nine-amino-acid synthetic peptide built to block alpha-MSH, the hormone that tells pigment cells to make melanin. It goes into brightening and dark-spot products as a gentler alternative to harsh lighteners. It is a cosmetic ingredient, not an FDA-approved drug, and there is no independent peer-reviewed clinical trial of it on its own.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Palmitoyl Hexapeptide-12 | Nonapeptide-1 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | VGVAPG repeats many times in elastin, the protein that lets skin snap back. When elastin breaks down, fragments like this are released, and back in 1984 researchers showed VGVAPG attracts fibroblasts and monocytes in the lab, which is the basis for calling it a matrikine: a matrix fragment that tells repair cells to show up and get to work. The palmitoyl tail makes the peptide fat-friendly enough to cross the outer skin layer. A 2025 ex vivo study added a twist: on human skin samples the peptide reached the epidermis, used the skin's own calcium to form a gel, and helped dried-out, lipid-stripped skin hold water and stay less stiff. That reads more like a barrier and film effect than proof of new elastin being built. | When skin is hit by UV, it releases alpha-MSH, which binds the MC1R receptor on melanocytes and switches on tyrosinase, the enzyme that makes melanin. Nonapeptide-1 is designed to sit in that receptor without switching it on, a competitive antagonist, so less of the tanning and pigment signal gets through. In cell studies it binds MC1R with high affinity and blocks alpha-MSH-driven melanosome dispersion at nanomolar levels, and it lowered tyrosinase and related pigment genes in human melanocytes. It is essentially the opposite of melanotan I and afamelanotide, which activate the same receptor to darken skin. The big unknown, as with most cosmetic peptides, is how much reaches melanocytes through intact skin. |
| Common Dosing | About 4% of the ingredient solution in a finished product Once or twice daily | Low percentage in a brightening serum Once or twice daily |
| Administration | Topical (serums, creams) | Topical (serums, creams) |
| Typical Duration | Manufacturer study ran one month; ongoing use for any maintained effect | Brightening claims are usually judged over 8 to 12 weeks; ongoing use |
| Best Time to Take | Morning and/or evening skincare routine | Morning (under sunscreen) and/or evening |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The best peer-reviewed work is a 2025 paper in ACS Applied Bio Materials (Ligorio and colleagues, with co-authors from Estee Lauder) that tracked the peptide in full-thickness human skin from a single donor. It showed penetration into the stratum corneum and epidermis, gel formation driven by calcium, reduced water loss and drying stress in delipidated skin (roughly comparable to 5 percent glycerol for drying stress), and stronger gels when mixed with collagen. Useful mechanistic data, but small samples and no living people. The appearance claims come from the manufacturer: a one-month, double-blind study in 10 women using 4 percent Biopeptide EL twice daily reported 33 percent better firmness and 20 percent better tone. That study is not in PubMed and is far too small to lean on. A separate 2023 trial of an elastin-like recombinant polypeptide built on the same VGVAPG repeat found improved elasticity after 28 days in 30 women, but that was a different molecule. Honest read: plausible biology, real skin penetration, no independent proof of visible results. | The evidence is thin and mostly commercial. Receptor binding and anti-pigment effects come from cell work and supplier data sheets. In a 2022 paper in Postepy Dermatologii i Alergologii (Chen and colleagues), nonapeptide-1 was used as a reference MC1R blocker in UVA-exposed human melanocytes and keratinocytes, where it reduced pigment pathway activity, but the study's focus was tea polyphenols, not the peptide. Ingredient databases describe the human data as small and manufacturer-generated. You will see claims online of a 12-week, 40-person trial where a cream with this peptide matched 4 percent hydroquinone for melasma, but we could not find a published, citable version, and even then it was a multi-ingredient cream. Fair summary: a well-designed molecule with a clear mechanism in cells, and very little real-world proof. Sunscreen still does more for dark spots than any single brightening peptide. |
Frequently Asked Questions: Palmitoyl Hexapeptide-12 vs Nonapeptide-1
What is the difference between Palmitoyl Hexapeptide-12 and Nonapeptide-1?
Palmitoyl Hexapeptide-12 is a skin & hair peptide that palmitoyl hexapeptide-12 is the six-amino-acid sequence vgvapg, a repeating piece of elastin, with a fatty acid tail attached so it can get into skin. it is sold under the trade name biopeptide el and pitched for firmness and elasticity, the bounce-back that fades with age. it is a cosmetic ingredient, not an fda-approved drug, and nobody has published an independent clinical trial showing it visibly changes skin. Nonapeptide-1 is a skin & hair peptide that nonapeptide-1, sold as melanostatine 5, is a nine-amino-acid synthetic peptide built to block alpha-msh, the hormone that tells pigment cells to make melanin. it goes into brightening and dark-spot products as a gentler alternative to harsh lighteners. it is a cosmetic ingredient, not an fda-approved drug, and there is no independent peer-reviewed clinical trial of it on its own. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Palmitoyl Hexapeptide-12 or Nonapeptide-1?
Neither is universally "better" - the choice depends on your specific goals. Palmitoyl Hexapeptide-12 is typically used for skin & hair purposes, while Nonapeptide-1 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Palmitoyl Hexapeptide-12 and Nonapeptide-1 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Palmitoyl Hexapeptide-12 and Nonapeptide-1 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.